Patents by Inventor Louis Fries
Louis Fries has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220354944Abstract: Disclosed herein are compositions and methods for inducing immune responses against both influenza and coronaviruses. Provided herein are compositions and methods of using the same, wherein the compositions comprise: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.Type: ApplicationFiled: May 4, 2022Publication date: November 10, 2022Inventors: Nita PATEL, Bin ZHOU, Mimi GUEBRE-XABIER, Jing-Hui TIAN, Alyse D. PORTNOFF, Michael J. MASSARE, Vivek SHINDE, Louis FRIES, Gale SMITH
-
Publication number: 20210137845Abstract: Disclosed herein are methods and nanoparticles suitable for use in reducing exacerbations in COPD patients. The methods and compositions advantageously reduce the incidence of hospitalization in COPD patients that occurs in response to environmental insults such as exposure to or infection by RSV. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.Type: ApplicationFiled: July 24, 2018Publication date: May 13, 2021Inventors: Gale SMITH, Ye LIU, Jing-Hui TIAN, Michael J. MASSARE, Sarathi BODDAPATI, Gregory GLENN, Louis FRIES, Iksung CHO
-
Patent number: 7121924Abstract: An attachable abrasive article comprises an abrasive member having an attachment device affixed thereto. The attachment device comprises a fastener having a flange thereon. Thermoplastic material is disposed between the flange and the abrasive article. The disclosure also concerns methods of making and using attachable abrasive articles.Type: GrantFiled: April 20, 2004Date of Patent: October 17, 2006Assignee: 3M Innovative Properties CompanyInventors: Peter Joseph Fritz, Richard Louis Fry
-
Patent number: 5968355Abstract: An apparatus is provided having a rotor inside a membrane for the aseptic vortex flow concentration of a liquid or semisolid dispersion which has a shed-resistant bearing interface so that unwanted bearing material does not contaminate the substances, e.g., pharmaceutical and biological materials, that are being processed.Type: GrantFiled: November 23, 1998Date of Patent: October 19, 1999Assignee: Matrix Pharmaceutical, Inc.Inventors: Richard Lee, Daniel Prows, Louis Fries
-
Patent number: 5925246Abstract: An apparatus is provided having a rotor inside a membrane for the aseptic vortex flow concentration of a liquid or semisolid dispersion which has a shed-resistant bearing interface so that unwanted bearing material does not contaminate the substances, e.g., pharmaceutical and biological materials, that are being processed.Type: GrantFiled: October 31, 1996Date of Patent: July 20, 1999Assignee: Matrix Pharmaceutical, Inc.Inventors: Richard Lee, Daniel Prows, Louis Fries
-
Patent number: 5874006Abstract: A process for the aseptic concentration of collagen from about 0.25% (w/w) suspensions to gels of 15% using vortex flow filtration with a variety of membrane types--ultrafiltration and microfiltration and polymeric and stainless steel is provided. The resulting gels are suitable for use in medical products and/or pharmaceutical formulations. This process achieves high degree of concentration in a closed system and at high flux with minimal trans-membrane pressure drop.Type: GrantFiled: October 31, 1996Date of Patent: February 23, 1999Assignee: Matrix Pharmaceutical, Inc.Inventors: Richard Lee, Daniel Prows, Louis Fries
-
Patent number: 5550188Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.Type: GrantFiled: June 7, 1995Date of Patent: August 27, 1996Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5543441Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: April 24, 1995Date of Patent: August 6, 1996Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5523348Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: August 18, 1994Date of Patent: June 4, 1996Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5446091Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.Type: GrantFiled: January 5, 1995Date of Patent: August 29, 1995Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5413791Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.Type: GrantFiled: February 17, 1994Date of Patent: May 9, 1995Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5383930Abstract: A device for correcting fine superficial facial lines which comprises a syringe fitted with a 31-33 gauge needle and an aqueous suspension of noncrosslinked fibrillar atelopeptide collagen contained within the syringe barrel, the concentration of collagen in the suspension being in the range of 10 to 50 mg/ml and the suspension exhibiting an extrusion plot in which there is a smooth substantially linear increase in force up to a substantially constant force in the range of 5 to 30 newtons.Type: GrantFiled: November 2, 1992Date of Patent: January 24, 1995Assignee: Collagen CorporationInventors: Ann Brannan, Roseann Burhenne, Frank A. Delustro, Thomas L. Smestad, Louis Fries, Rees M. Orland
-
Patent number: 5376375Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: January 5, 1994Date of Patent: December 27, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5366498Abstract: A device for correcting fine superficial facial lines which comprises a syringe fitted with a 31-33 gauge needle and an aqueous suspension of noncrosslinked fibrillar atelopeptide collagen contained within the syringe barrel, the concentration of collagen in the suspension being in the range of 10 to 50 mg/ml and the suspension exhibiting an extrusion plot in which there is a smooth substantially linear increase in force up to a substantially constant force in the range of 5 to 30 newtons.Type: GrantFiled: February 10, 1993Date of Patent: November 22, 1994Assignee: Collagen CorporationInventors: Ann Brannan, Roseann Burhenne, Frank A. Delustro, Thomas L. Smestad, Louis Fries, Rees M. Orland
-
Patent number: 5328955Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding atelopeptide collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugates. The atelopeptide collagen can be type I, type II or type III and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The collagen-polymer conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object.Type: GrantFiled: July 30, 1992Date of Patent: July 12, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5324775Abstract: Pharmaceutically acceptable, non-immunogenic compositions are formed by covalently binding biologically inactive, natural, biocompatible polymer to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide biocompatible conjugates. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having a weight average molecular weight over a range of from about 100 to about 20,000. The compositions may include other components such as liquid, pharmaceutically acceptable, carriers to form injectable formulations, and/or biologically active proteins such as growth factors. The conjugates of the invention generally contain large amounts of water when formed. The conjugates can be dehydrated to form a relatively solid object. The dehydrated, solid object can be ground into particles which can be suspended in a non-aqueous fluid such as an oil and injected into a living (preferably human) being for the purpose of providing soft tissue augmentation.Type: GrantFiled: July 2, 1992Date of Patent: June 28, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5308889Abstract: Medical articles in the form of strings are formed by covalently binding collagen to pharmaceutically pure, synthetic, hydrophilic polymers via specific types of chemical bonds to provide collagen/polymer conjugate formulations which are extruded to make the strings. The collagen may be recombinantly produced human collagen or collagen extracted from any source, such as a bovine source or human placenta, and purified and can be of various types and may be fibrillar or non-fibrillar. The synthetic hydrophilic polymer may be polyethylene glycol and derivatives thereof having an average molecular weight over a range of from about 100 to about 20,000. The string can be designed to incorporate other components such as fluid, pharmaceutically acceptable carriers to form injectable formulations, and/or biologically active proteins such as growth factors or cytokines. The strings contain large amounts of water when extruded and may then be dehydrated to form relatively solid but flexible strings.Type: GrantFiled: December 2, 1992Date of Patent: May 3, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Louis Fries, Ramesh Damani, Kimberly McCullough, Frank DeLustro
-
Patent number: 5306500Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: August 23, 1993Date of Patent: April 26, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5304595Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: December 30, 1992Date of Patent: April 19, 1994Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz
-
Patent number: 5264214Abstract: Collagen, particularly atelopeptide collagen, exhibits improved handling characteristics when chemically conjugated and/or crosslinked with a synthetic hydrophilic polymer.Type: GrantFiled: August 14, 1992Date of Patent: November 23, 1993Assignee: Collagen CorporationInventors: Woonza Rhee, Donald G. Wallace, Alan S. Michaels, Ramon A. Burns, Jr., Louis Fries, Frank DeLustro, Hanne Bentz